Immunovant (IMVT) reported a fiscal Q4 net loss Wednesday of $0.73 per diluted share, widening from a $0.64 loss a year earlier.

Analysts polled by FactSet expected a $0.59 loss.

As expected, no revenue was reported for the quarter ended March 31.

The company's cash and cash equivalents were about $902.1 million as of March 31, providing runway for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease, it said.

Immunovant shares were up 27% in premarket activity.